| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1002/14651858.CD004034.PUB2 |
| P698 | PubMed publication ID | 16625595 |
| P50 | author | Bernadette McGuinness | Q57081640 |
| P2093 | author name string | Peter Passmore | |
| Roger Bullock | |||
| Stephen Todd | |||
| P2860 | cites work | Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 |
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group | Q28328155 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Is there bias in the publication of individual patient data meta-analyses? | Q30606252 | ||
| Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data | Q30744678 | ||
| Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial | Q31834521 | ||
| Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur trial. Syst-Eur Trial Investigators | Q31987904 | ||
| Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A | Q33989952 | ||
| Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). | Q34223561 | ||
| Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | Q34327991 | ||
| Meta-analysis of the literature or of individual patient data: is there a difference? | Q34334544 | ||
| The age-dependent relation of blood pressure to cognitive function and dementia | Q36201875 | ||
| Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults | Q36598021 | ||
| Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group | Q36790212 | ||
| Quality of life on randomized treatment for isolated systolic hypertension: results from the Syst-Eur Trial | Q39006198 | ||
| The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans | Q39546865 | ||
| Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. | Q43533201 | ||
| One-year study of felodipine or placebo for stage 1 isolated systolic hypertension | Q43801322 | ||
| The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study | Q44175666 | ||
| The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial | Q44417511 | ||
| Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease | Q44438340 | ||
| Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study | Q44704643 | ||
| Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). | Q44810280 | ||
| The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization | Q44981441 | ||
| Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: introduction. | Q46003482 | ||
| The effects of antihypertensive treatment on cognitive function: results from the HOPE study | Q47633435 | ||
| Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial | Q48359732 | ||
| A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group. | Q48873771 | ||
| Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. | Q50850450 | ||
| Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. | Q50934595 | ||
| A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population. | Q51019542 | ||
| Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. | Q51996137 | ||
| Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. | Q52061053 | ||
| Bias in treatment assignment in controlled clinical trials. | Q52874177 | ||
| Antihypertensive drugs and incidence of dementia: the Rotterdam Study | Q57782073 | ||
| Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study | Q57782154 | ||
| Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) | Q68323341 | ||
| Blood pressure and cognitive performance. The Framingham Study | Q69461525 | ||
| Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group | Q69928982 | ||
| Reexamining the quality of life of hypertensive patients. A new self-structured measure | Q70644406 | ||
| 15-year longitudinal study of blood pressure and dementia | Q71021081 | ||
| Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans | Q78358118 | ||
| P921 | main subject | dementia | Q83030 |
| cerebrovascular disease | Q3010352 | ||
| cognitive dysfunction | Q57859955 | ||
| P577 | publication date | 2006-04-19 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia |
| Q51902565 | A survey of attitudes of clinicians towards the diagnosis and treatment of mild cognitive impairment in Australia and New Zealand. |
| Q49404486 | Alzheimer disease prevention: New optimism |
| Q33897464 | Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study |
| Q36670162 | Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging |
| Q38571859 | Antihypertensive Therapies and Cognitive Function: a Review |
| Q33678373 | Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). |
| Q30410885 | Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. |
| Q38029515 | Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention |
| Q34409397 | Blood pressure and dementia - a comprehensive review |
| Q37593677 | Blood pressure control in the elderly: can you have too much of a good thing? |
| Q24240206 | Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia |
| Q37061183 | Cognition and diabetes: a lifespan perspective. |
| Q40878958 | Cognitive impact of lacunar infarcts and white matter hyperintensity volume. |
| Q36787352 | Dementia syndromes: evaluation and treatment |
| Q36811092 | Heart disease as a risk factor for dementia |
| Q35178724 | Hypertension and cognitive function |
| Q37551271 | Hypertension, dementia, and antihypertensive treatment: implications for the very elderly. |
| Q28286628 | Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial |
| Q35094993 | Integrating health into cognitive aging: toward a preventive cognitive neuroscience of aging |
| Q37708614 | Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension |
| Q37954450 | Modeling the dementia epidemic. |
| Q92673458 | Neurovascular and Cognitive Dysfunction in Hypertension |
| Q43252108 | Posterior paralimbic and frontal metabolite impairments in asymptomatic hypertension with different treatment outcomes |
| Q33544151 | Promoting successful cognitive aging: a comprehensive review |
| Q55261553 | Regional myocardial motion in patients with mild cognitive impairment: a pilot study. |
| Q37440412 | Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study |
| Q36896787 | The association between the prevalence, treatment and control of hypertension and the risk of mild cognitive impairment in an elderly urban population in China |
| Q79219460 | Update on the management of hypertension to prevent stroke |
| Q33687724 | Validating the Framingham Hypertension Risk Score: results from the Whitehall II study |
| Q37085101 | Vascular cognitive impairment: current concepts and clinical developments |
| Q37017429 | Vascular dementia: pharmacological treatment approaches and perspectives |
| Q36812802 | Vascular risk factors, cognitive decline, and dementia |
| Q33305144 | What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures |
Search more.